Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.300
+0.030 (2.36%)
At close: Jun 26, 2026, 4:00 PM EDT
1.327
+0.027 (2.07%)
After-hours: Jun 26, 2026, 7:58 PM EDT
Allarity Therapeutics Employees
As of December 31, 2025, Allarity Therapeutics had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$43,125
Profits / Employee
-$1,406,125
Market Cap
20.68M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Longeveron | 38 |
| Palatin Technologies | 29 |
| Lipocine | 14 |
| NewcelX | 12 |
| Cellectar Biosciences | 11 |
| VYNE Therapeutics | 10 |
| AEON Biopharma | 8 |
ALLR News
- 9 days ago - Allarity to present trial-in-progress poster on Phase 2 stenoparib trial - TheFly
- 9 days ago - Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026 - GlobeNewsWire
- 6 weeks ago - Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers - GlobeNewsWire
- 7 weeks ago - Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm - GlobeNewsWire
- 7 weeks ago - Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign - GlobeNewsWire
- 2 months ago - Allarity receives notice of allowance from USPTO - TheFly
- 2 months ago - Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office - GlobeNewsWire
- 3 months ago - Allarity Therapeutics Reports Full Year 2025 Financial Results and Corporate Progress - GlobeNewsWire